Explore the words cloud of the NEWCARBOVAX project. It provides you a very rough idea of what is the project "NEWCARBOVAX" about.
The following table provides information about the project.
UNIVERSITA DEGLI STUDI DI MILANO
|Coordinator Country||Italy [IT]|
|Total cost||244˙269 €|
|EC max contribution||244˙269 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2017-01-01 to 2019-12-31|
Take a look of project's partnership.
|1||UNIVERSITA DEGLI STUDI DI MILANO||IT (MILANO)||coordinator||244˙269.00|
|2||GLAXOSMITHKLINE VACCINES SRL||IT (SIENA)||participant||0.00|
|3||PRESIDENT AND FELLOWS OF HARVARD COLLEGE||US (CAMBRIDGE)||partner||0.00|
Glycoconjugate vaccines have provided enormous health benefits globally, but they have been less successful in some populations at high risk for developing disease. They are composed by a sugar antigen covalently linked to a carrier protein. The traditional hypothesis of immune activation by glycoconjugate vaccines suggests that only peptides generated from glycoconjugate processing can be presented to and recognized by T cells, and this contribution is crucial for their immunogenicity. In most cases, conjugation processes have been set-up empirically. Recently, new findings offer a rational explanation for how conjugates work and may render vaccine development a more straightforward process. In contrast with the classical mechanism, this new model suggests that carbohydrate presentation to the T cell by antigen-presenting cell may strongly enhance antibody response. The key strategy is to conjugate the carbohydrate to peptides which anchor the conjugate via MHC class II and allow the sugar epitope to be presented via the T cell receptor. Application of this principle resulted in a GBSIII vaccine strongly protective in a mouse model and 50–100 times more immunogenic than a traditional vaccine composed by random linking of the sugar on a protein carrier. Although the principle has been demonstrated much remains to be done to generally apply the concept to generate vaccines for clinical use. In the proposed study, we will extend the approach by analysing different variables (peptide carrier, glycan chain length, conjugation chemistry and microbial antigen), with the aim of using the increased understanding of basic immunological mechanisms to develop a new translational platform for optimized and cost-effective carbohydrate-based vaccines. Innovative strategies of conjugation chemistry will be also evaluated to generate new therapeutics with chemical properties designed in light of specific information on antigen presentation.
|year||authors and title||journal||last update|
Giuseppe Stefanetti, Nihal Okan, Avner Fink, Erica Gardner, Dennis L. Kasper
Glycoconjugate vaccine using a genetically modified O antigen induces protective antibodies to Francisella tularensis
published pages: 7062-7070, ISSN: 0027-8424, DOI: 10.1073/pnas.1900144116
|Proceedings of the National Academy of Sciences 116/14||2020-02-28|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEWCARBOVAX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NEWCARBOVAX" are provided by the European Opendata Portal: CORDIS opendata.
How other minds are represented in the human brain: Neural computations underlying Theory of MindRead More
Shaping the European Migration Policy: the role of the security industryRead More
New treatments and novel diagnostic tests for neonatal seizures based on purinergic signaling.Read More